Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company whose news flow is driven by clinical trial milestones, regulatory interactions, strategic collaborations, and corporate updates. The company regularly issues press releases detailing progress across a deep pipeline of targeted small molecules and antibody-drug conjugates (ADCs) for molecularly defined solid tumors.
News related to IDYA often highlights developments in its lead program darovasertib, an oral protein kinase C inhibitor in clinical trials for uveal melanoma. Updates include enrollment milestones, progression-free survival and overall survival data from trials such as OptimUM-01 and OptimUM-02 in metastatic uveal melanoma, and neoadjuvant data from OptimUM-09 and the Phase 3 OptimUM-10 trial in primary uveal melanoma. IDEAYA also reports on regulatory designations for darovasertib and its collaboration with Servier for rights outside the United States.
Investors following IDEAYA news will see frequent announcements on its broader pipeline, including IDE397 for MTAP-deleted urothelial cancer and NSCLC, IDE849 for small cell lung cancer and neuroendocrine carcinomas, IDE161 as a PARG inhibitor for ADC combinations, IDE034 as a bispecific B7H3/PTK7 TOP1 ADC, IDE574 as a KAT6/7 dual inhibitor, and IDE892 as a PRMT5 inhibitor. Press releases cover IND submissions and clearances, Phase 1 and Phase 2 data readouts, and plans for upcoming medical conference presentations.
IDYA news also includes financial results, cash runway commentary, licensing transactions such as the Servier darovasertib agreement, and governance or compensation updates reported via SEC filings and corporate press releases. Tracking this news stream provides insight into IDEAYA’s clinical progress, partnering activity, and evolving precision oncology strategy.
IDEAYA Biosciences (NASDAQ:IDYA) will host its 10-Year Anniversary R&D Day on September 8, 2025 in New York from 8:00-10:30am EST. The event will showcase the company's progress and future growth strategy, featuring presentations on multiple clinical programs.
Key highlights include new clinical data presentations on darovasertib in neoadjuvant uveal melanoma, IDE849 (DLL3 TOP1 ADC), and IDE397 (MAT2A). Dr. Arun D. Singh from Cleveland Clinic will present Phase 2 trial data of darovasertib and discuss the Phase 3 OptimUM-10 trial design. The agenda also covers IDE892 (PRMT5) development and the company's AI/ML discovery capabilities.
IDEAYA Biosciences (Nasdaq: IDYA) reported Q2 2025 financial results and significant pipeline progress. The company maintains a strong financial position with $992 million in cash, expected to fund operations into 2029. Key developments include the Phase 2/3 trial of darovasertib/crizotinib combination in metastatic uveal melanoma, with over 350 patients enrolled and median PFS data expected by year-end 2025.
The company plans three IND submissions by year-end 2025 and will present multiple clinical data updates across its pipeline. Notable upcoming milestones include Phase 2 data from over 90 primary uveal melanoma patients at ESMO and Phase 1 data from over 70 SCLC patients treated with IDE849 at WCLC. Financial results show R&D expenses of $74.2 million and a net loss of $77.5 million for Q2 2025.
[ "Strong cash position of $992 million expected to fund operations into 2029", "Phase 2/3 trial of darovasertib/crizotinib successfully enrolled over 350 patients", "Multiple near-term catalysts with six clinical data updates expected by year-end", "Three new IND submissions planned by year-end 2025", "Expansion of commercial and medical affairs team in preparation for potential product launch" ]IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $24.35 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ:IDYA) announced that results from their Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma will be presented at ESMO 2025 in Berlin. The study includes data from over 90 patients across plaque brachytherapy and enucleation-eligible cohorts.
The presentation will highlight darovasertib's potential impact on disease management, particularly notable as it has received FDA Breakthrough Therapy Designation for neoadjuvant use in uveal melanoma patients requiring enucleation. The company has also initiated OptimUM-10, a global Phase 3 neoadjuvant registrational trial, in Q3 2025.
IDEAYA Biosciences (Nasdaq: IDYA) has announced its upcoming 10-Year Anniversary R&D Day, scheduled for September 8, 2025, from 8:00 AM to 10:00 AM ET in New York City. The event will be accessible both in-person and virtually.
The R&D Day will feature presentations of multiple clinical data updates across the company's pipeline, along with discussions about future growth drivers and upcoming milestones. The event will include presentations from IDEAYA's senior leadership team and key opinion leaders in precision medicine oncology.
CEO Yujiro S. Hata will outline the company's strategic vision, priority scientific focus areas, and emerging clinical pipeline as IDEAYA positions itself as a global leader in precision medicine oncology.
IDEAYA Biosciences (NASDAQ:IDYA) and Hengrui Pharmaceuticals announced an upcoming oral presentation at the IASLC 2025 World Conference on Lung Cancer featuring clinical data for IDE849 (SHR-4849), their potential first-in-class DLL3-TOP1 antibody drug conjugate (ADC).
The presentation will showcase efficacy and safety data from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing Phase 1 trial in China. Additionally, IDEAYA initiated a U.S. Phase 1 trial of IDE849 in SCLC patients in Q3 2025. The company will also present a poster demonstrating combination mechanism data between TOP1-payload based ADCs and IDE161, their proprietary PARG inhibitor.
IDE849 targets DLL3, which is upregulated in multiple solid tumors including SCLC, neuroendocrine tumors, non-small cell lung cancer, and melanoma. The presentations will take place at the conference in Barcelona, Spain, from September 6-9, 2025.
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, will participate in the 2025 BTIG Virtual Biotechnology Conference on July 29th, 2025. The company's President and CEO, Yujiro S. Hata, will engage in a fireside chat at 4:40 PM ET, hosted by BTIG's Director of Biotechnology Research Analysis, Justin Zelin.
The event will be accessible via live audio webcast through the company's investor relations website, with replay available for 30 days after the event.
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 95,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $22.29 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.